Several advances in kidney cancer have occurred over the past decade, including the discovery of mutations in chromatin remodelling genes and genomic heterogeneity in clear cell renal cell carcinoma (ccRCC). Altered metabolic patterns in ccRCC and papillary RCC have become apparent, and new drugs for ccRCC have been approved.
Between 2004 and 2014, remarkable improvements in our understanding of the genetic basis of renal cell carcinoma (RCC) and in the treatment of patients with advanced kidney cancer have been realized. These developments include the approval by the FDA of seven agents targeting the VHL/HIF pathway for patients with advanced-stage RCC, and the identification of gene mutations in kidney tumours. These advances built on the progress of the previous decade, which had seen the discovery of the VHL gene, the identification of mutations of the VHL gene in clear cell RCC (ccRCC) and the delineation of the VHL pathway. Mutations in MET and their involvement in hereditary type 1 papil lary kidney cancer were also identified, and FLCN gene mutations were shown to be the primary cause for inherited chromophobe kidney cancer associated with Birt-Hogg-Dubé syndrome. Mutations in the FH gene, which encodes a Krebs cycle enzyme, were also identified as the cause of most cases of hereditary type 2 papillary kidney cancer associated with hereditary leiomyo matosis and renal cell carcinoma (HLRCC). The understanding that kidney cancer is made up of a number of different types of cancer, each having different histology, clinical course and genetic causes, has aided p rogress in treating this disease.
At the start of this decade, only IL-2 was approved for the treatment of patients with advanced-stage kidney cancer. The deline ation of the VHL/HIF pathway and its role in RCC in the 1990s provided the foundation for the development of targeted t herapeutic agents for patients with this disease. Since then, several randomized, double-blind trials have identified effective agents for the treatment of kidney cancer, targeting vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) pathways. The first targeted agent against the VEGF and PDGF receptors, sorafenib, was approved for patients with advanced-stage kidney cancer in 2005. Patients treated with sorafenib were shown to have a median progression-free survival (PFS) of 5.5 months, compared with 2.8 months for those given placebo. In 2006, sunitinib, which also targets the VEGF and PDGF receptors, was approved. Sunitinib therapy was associated with an 11-month PFS compared with 5 months for patients treated with IFN-α, a nonspecific immune modulator that has been used for a number of years in patients with advanced-stage kidney cancer.
The mTOR pathway is an important kidney cancer pathway that in directly influences VEGF and PDGF expression by affecting HIF translation. In 2007, temsirolimus, an agent that targets mTOR, was approved after patients with poor prognostic factors experienced a PFS of 10.9 months on the drug compared with 7.3 months for those treated with IFN-α. Three agents were approved in 2009: the first, everolimus, also targets the mTOR pathway and was approved for patients with RCC who had previously received sunitinib or sorafenib therapy. Those treated with everolimus demonstrated PFS of 4.0 months compared with 1.9 months for placebo. The second drug, bevacizumab (a monoclonal antibody against VEGF-A) was approved for use in conjunction with IFN-α in patients with advanced-stage RCC. Treatment with bevacizumab and IFN-α increased PFS to a median of 10.2 months, compared with 5.4 months in patients treated with IFN-α alone. Finally, pazopanib, a multikinase inhibitor targeting the VEGF and PDGF receptors, was also approved to treat patients with advanced-stage RCC. Pazopanib therapy was found to be associ ated with a PFS of 9.2 months compared with 4.2 months for patients given a placebo. In January 2012, axitinib, another multikinase inhibitor, was the seventh targeted therapeutic agent this decade approved by the FDA for the treatment of patients with kidney cancer. Patients treated with axitinib were found to have a median PFS of 6.7 months compared with 4.7 months for patient receiving sorafenib. 1 These accomplishments provided physicians with a range of targeted agents to treat patients for the first time. Although the response rates for treatment with agents such as sunitinib or pazopanib are reported to be approximately 35%, and there have been improvements in PFS and overall survival, few treatments result in a complete response; most patients eventually progress and many die of their cancer. This eventuality could be because targeting the VHL/HIF pathway with currently available therapies is inadequate, or because there are other genes associated with the initiation or progression of kidney cancer that are not currently being targeted.
Exciting new insights into the genetic basis of ccRCC came from reports identifying mutations in several chromatin remodelling, histone modifying and SWItch/ SNF nucleosome remodelling complex genes. 2, 3 When The Cancer Genome Atlas Research Network performed a comprehensive molecu lar characterization of genetic changes associated with ccRCC, 19 significantly mutated genes were identified. After VHL, the most commonly mutated '' …understanding that kidney cancer is made up of a number of different types of cancer … aided progress… ''
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genes were the chromosome 3 chromatin remodel ling genes-PBRM1, SETD2 and BAP1. Mutations of BAP1 were found to be correlated with poor survival. Furthermore, mutations were identified in KDM5C, TP53 and the PI3K/Akt pathway genes (PTEN, MTOR and PIK3CA). It was also demonstrated that the PI3K/Akt pathway has an important role in tumour progression. Integrative analysis showed that high-grade, high-stage, low-survival ccRCC tumours demonstrated evidence of a Warburg-like metabolic shift, involving downregulation of genes involved in the Krebs cycle, decreased AMPK and increased fatty acid synthesis. 4 These findings, which are consistent with the isotopomer spectral analysis of VHL -/-ccRCC and FH -/-type 2 papillary RCC, reveal that a dependence on reductive glutamine metabolism for lipid biosyn thesis is important in kidney cancer and could provide the foundation for the development of novel forms of therapy targeting the m etabolic basis of RCC. 5, 6 To further understand the genetic basis of ccRCC, Gerlinger and colleagues 7 reported the use of multiregion exome sequencing (M-seq) to study the genomic architecture and evolution of ccRCC, and found extensive genomic heterogeneity. 'Truncal' mutations of the VHL gene were found in every segment of each sample, whereas driver mutations in the chromatin remodelling genes SETD2, BAP1 and KDM5C, as well as TP53 and genes in the PI3K/mTOR pathway (MTOR, PIK3CA, PTEN and TSC2), were found only in some segments of the tumours; these were labeled 'branch' mutations. Of all the driver mutations, 75% were subclonal, and intratumoral heterogeneity increased with the number of biopsy specimens analysed. 7 These findings raise profound questions about the most effective way to detect driver mutations in ccRCC, and which gene pathways to target. Should M-seq be performed on primary tumours and/or metastatic sites to identify common driver mutations that are associated with the initiation and progression of kidney cancer? Do both the truncal and branching driver gene pathways need to be targeted, singularly or together, to develop an effective form of therapy for ccRCC? These critical questions need to be answered in the next decade in kidney cancer research.
Although a number of novel therapies for patients with advanced-stage ccRCC have been developed over the past decade, we still have no effective treatment for patients with advanced-stage papillary kidney cancer. Significant insight into papil lary kidney cancer has come from studies of the hereditary form of type 2 papillary renal carcinoma found in patients with HLRCC, caused by mutation of the FH gene. FH-deficient kidney cancer cells, which exhibit impaired oxidative phosphory lation, undergo a Warburg-like metabolic shift to aerobic glycolysis with decreased AMPK and increased mTOR and HIF-1α levels. 8 Studies by Adam et al. 9 and Ooi et al. 10 showed upregulation of the antioxidant signalling pathways in both FH-deficient kidney cancer and sporadic (non-inherited) papillary kidney cancer. Elevated fumarate in FH-deficient RCC targets and inactivates the electrophile sensor KEAP1, which results in NRF2 accumulation and upregulation of antioxidant response element-controlled genes, such as NQO and the GST family genes. These genes are critical for the survival of cancers, which are characterized by high levels of oxidative stress, such as hereditary and sporadic type 2 papillary kidney cancer. 9, 10 This pathway provides a number of opportunities for the development of targeted therapeutic approaches for patients with advanced-stage papillary RCC.
Overall, this past decade has seen a num ber of historic advances towards the understanding and treatment of RCC, with the FDA approving seven drugs targeting the VHL/HIF pathway for patients with advanced-stage kid ney cancer. Figure 1 illustrates the exten sive genomic heterogeneity of ccRCC, which poses a significant therapeutic challenge; intense efforts are underway to translate discoveries into new therapeutic approaches for patients. The finding of a Warburg-like metabolic shift and the dependence of the KEAP1/ NRF2 antioxidant pathway in both clear cell and papillary RCC provides promising opportunities for the development of therapies t argeting the m etabolic basis of kidney cancer. 
